Abstract:
Based on information associated with users, a social networking system recommends one or more groups for a target user to join or to create. Characteristics of the target user, characteristics of users connected to the target user, characteristics of candidate groups in the social networking system may be used to identify groups for recommendation. The social networking system may provide questions to the target user and recommend a group to the target user based on received answers to the questions. For example, the answers to the provided question identify one or more characteristics of the target user, which are used to select a group for recommendation. Additionally, the social networking system may recommend additional users for the target user to add or invite to a group based on characteristics of the target user, the additional users, and/or the group.
Abstract:
A pilot and channel estimation method for SDMA MIMO transmission downlink is provided in the present invention, and the method provides possibility for saving the orthogonal pilot resources; the pilot signals of different users in the transmitting antenna domain can occupy the same time-frequency resources, and thereby the pilot overhead of system resources can be reduced greatly; the method includes: for the MIMO transmission downlink that employs pre-coding for SDMA, taking the quantity of orthogonal pilot resources occupied by the users in the pre-coding domain as the number of data streams that can be transmitted or the number of spatial dimensions occupied first, at the transmitting end of the base station; then, performing SDMA transmission pre-coding for the orthogonal pilots in the pre-coding domain in the same way as the data signals, to obtain the pilot signals of the users in the transmitting antenna domain; wherein, the pilots of the users in the pre-coding domain can be orthogonal in the frequency domain or code domain, and the pilots of different users in the pre-coding domain can be identical or not identical to each other; the pilot signals of different users in the transmitting antenna domain can occupy the same time-frequency resources.
Abstract:
The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.
Abstract:
A multi-antenna channel estimation method based on polyphase decomposition includes: receiving frequency domain received signals transformed using discrete fourier transformation (DFT) in pilot symbols; performing phase correction on the frequency domain received signals; performing polyphase decomposition on the frequency domain received signals which are corrected using phase correction and acquiring polyphase signals; performing interpolation on the polyphase signals and acquiring the estimation values of the multi-antenna channel parameters with various linear combinations on each frequency; acquiring decorrelation array based on the pilot structure of the transmission antenna and decorrelating the estimation values of the multi-antenna channel parameters with various linear combination on each frequency using the decorrelation array and acquiring channel parameters of the pilot symbols on each frequency; acquiring channel parameters of data symbols based on the channel parameters of the pilot symbols. With the present invention, the inversion problem in multi-antenna channel estimation is avoided with lower complexity, and results of the multi-antenna channel estimation method become more accurate since the DFT and filtering are performed in the interpolation after polyphase decomposition.
Abstract:
Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity, including inflammatory and immune diseases, having the structure of formula (I): an enantiomer, diastereomer, or tautomer thereof, or a prodrug ester thereof, or a pharmaceutically-acceptable salt thereof, in which: Z is heterocyclo or heteroaryl; A is a 5- to 8-membered carbocyclic ring or a 5- to 8-membered heterocyclic ring; B is a cycloalkyl, cycloalkenyl, aryl, heterocyclo, or heteroaryl ring, wherein each ring is fused to the A ring on adjacent atoms and optionally substituted by one to four groups which are the same or different and are independently selected from R5, R6, R7, and R8; J1, J2, and J3 are at each occurrence the same or different and are independently -A1QA2-; Q is a bond, O, S, S(O), or S(O)2; A1 and A2 are the same or different and are at each occurrence independently selected from a bond, C1-3alkylene, substituted C1-3alkylene, C2-4alkenylene, and substituted C2-4alkenylene, provided that A1 and A2 are chosen so that ring A is a 5- to 8-membered carbocyclic or heterocyclic ring; R1 to R11 are as defined herein. Also provided are pharmaceutical compositions and methods of treating inflammatory- or immune-associated diseases and obesity and diabetes employing said compounds.
Abstract:
The present invention describes a method of reducing the enzymatic digestion rates of starch granules in food, particularly rice-based food. The method is carried out by encapsulating the starch granules with a reaction compound formed by the chemical reaction of at least a crosslinkable polysaccharide that has been pre-mixed with the ingredients for food production, and at least a crosslinking agent. The invention also relates to a process of preparing food products by incorporating the method of the present invention and food products produced by the present method.
Abstract:
A level shifter circuit for shifting from a first voltage level technology (such as 0.9 volt) to a second level voltage technology (such as 3.3 volt) with increased switching speed. The increased speed is achieved by adding a boost circuit to the pull-up transistors to boost the switching speed and shut itself down after the transition. The level shifter circuit does not require intermediate level transistors or intermediate level voltage sources.
Abstract:
Non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) or an enantiomer, a diastereomer, a pharmaceutically acceptable salt, or hydrate thereof, where J is selected from NR1 or C(R4)(R4a); K is selected from NR2 or C(R5)(R5a); L is selected from NR3 or C(R6)(R6a); and A, X, Y, R1, R2, R3, R4, R4a, R5, R5a, R6, R6a, R8, R10, R11, and n are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.
Abstract:
An interface driver circuit includes a plurality of delay cells. Each delay cell includes a data input, a delayed data output configured to communicate with the data input of an adjacent one of the plurality of delay cells. A delay time input is configured to set a delay value between receiving data at the data input and generating the delayed data output. A plurality of predrivers is configured to receive an output enable signal. A plurality of predrivers is configured to receive a corresponding one of the plurality of delayed data outputs. A plurality of predrivers is configured to generate a predriver output signal based on the output enable signal and the corresponding one of the plurality of delayed data outputs. The output enable signal enables and disables the plurality of predrivers and is independent of data of each delayed data output.